LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

Начало・Списък с акции・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

20.75 1.32

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

20.12

Максимум

20.79

Ключови измерители
By Trading Economics
Приходи	11M -61M
Продажби	7.9M 46M
Марж на печалбата	-132.36
Служители	270
EBITDA	6.3M -58M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+88.02% upside

Дивиденти
By Dow Jones
Следващи печалби	26.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	600M 1.7B
Предишно отваряне	19.43
Предишно затваряне	20.75

Настроения в новините

By Acuity

50%

161 / 351 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

9.91 / 14.15 Подкрепа & съпротива

Syndax Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

24.02.2026 г., 23:07 ч. UTC

Печалби

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24.02.2026 г., 23:01 ч. UTC

Печалби

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24.02.2026 г., 22:59 ч. UTC

Печалби

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

24.02.2026 г., 22:42 ч. UTC

Печалби

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

24.02.2026 г., 22:24 ч. UTC

Придобивния, сливания и поглъщания

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

24.02.2026 г., 23:46 ч. UTC

Пазарно говорене

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

24.02.2026 г., 23:36 ч. UTC

Пазарно говорене

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

24.02.2026 г., 23:30 ч. UTC

Пазарно говорене

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

24.02.2026 г., 23:20 ч. UTC

Пазарно говорене

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

24.02.2026 г., 23:20 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

24.02.2026 г., 23:16 ч. UTC

Печалби

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

24.02.2026 г., 23:13 ч. UTC

Печалби

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

24.02.2026 г., 23:12 ч. UTC

Печалби

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

24.02.2026 г., 23:10 ч. UTC

Печалби

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

24.02.2026 г., 23:10 ч. UTC

Печалби

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

24.02.2026 г., 23:08 ч. UTC

Печалби

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

24.02.2026 г., 23:07 ч. UTC

Печалби

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

24.02.2026 г., 22:52 ч. UTC

Печалби

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24.02.2026 г., 22:46 ч. UTC

Печалби

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24.02.2026 г., 22:31 ч. UTC

Придобивния, сливания и поглъщания

Warner Receives New Bid From Paramount -- 3rd Update

24.02.2026 г., 22:29 ч. UTC

Печалби

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

24.02.2026 г., 22:28 ч. UTC

Печалби

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

24.02.2026 г., 22:27 ч. UTC

Печалби

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

24.02.2026 г., 22:27 ч. UTC

Печалби

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

24.02.2026 г., 22:25 ч. UTC

Печалби

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

24.02.2026 г., 22:24 ч. UTC

Печалби

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

24.02.2026 г., 22:23 ч. UTC

Печалби

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

24.02.2026 г., 22:22 ч. UTC

Печалби

Woolworths Interim Dividend 45 Australian Cents/Share

24.02.2026 г., 22:22 ч. UTC

Печалби

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

24.02.2026 г., 22:21 ч. UTC

Печалби

Woolworths 1H Statutory Net Profit A$374 Mln, Down 49.4%

Сравнение с други в отрасъла

Ценова промяна

Syndax Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

88.02% нагоре

12-месечна прогноза

Среден 38.6 USD 88.02%

Висок 56 USD

Нисък 28 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Syndax Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на Syndax Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

9.91 / 14.15Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Настроение

By Acuity

161 / 351 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.